European regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU.
News
AZ buys Ionis’ NASH candidate
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million
Theresa May unveils £75m prostate cancer research fund
Prime Minister Theresa May has announced an investment of £75 million into research targeting earlier diagnosis and better treatment for men with prostate cancer.
SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
MSD’s Keytruda bags another trial success in NSCLC
MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.
NHS England backs new innovations for NHS use
NHS England has unveiled the new technologies that are to be fast-tracked into NHS use via the Innovation and Technology Payment Programme (ITP).
NICE u-turn sees Roche’s Tecentriq backed for lung cancer
Following an earlier negative decision NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.
New US approval for Clovis’ Rubraca
Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.
Incyte/MSD’s immunotherapy combo fails in Phase III
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Novartis snaps up AveXis in $8.7bn deal
Novartis is buying US gene therapy group AveXis in a deal valued at $8.7 billion.
Last chance to enter or nominate in Sales Manager of the Year
With hundreds of nominations received so far, and two weeks still left until the closing date, the PharmaTimes Sales Representative of the Year is set be an exciting and highly representative competition.
A fantastic L&D opportunity for sales managers and teams
The PharmaTimes Sales Manager of the Year competition, part of the prestigious annual Sales Awards, is a fantastic learning and development opportunity for sales managers and teams.
PharmaTimes Media announces the launch of the prestigious Sales Awards for 2017
Open to pharma sales representatives and sales managers, candidates in this prominent industry competition are both nominated and judged by healthcare professionals. The PharmaTimes Sales Awards therefore delivers truly meaningful recognition for pharma sales professionals, from the people who matter most: their customers.
HCPs asked to name their Sales Representative of the Year
The PharmaTimes Sales Awards is the ONLY industry wide competition driven by the customer from start to finish…from initial nomination, through to robust assessment, all the way to high quality feedback.
Time is running out to enter Sales Manager of the Year 2016
Compete against your peers in unique, on-the day, competency-based challenges for the chance to win the prestigious Pharma.
